Eli Lilly has removed the commonly used clinical measure of body mass index from the FDA label for its weight loss drug ...

The SEC said Tuesday that it settled charges filed against Kiromic Biopharma, a tiny immuno-oncology startup based in Texas, ...

Coherus BioSciences' stock surged on Tuesday after the company announced plans to sell off the last biosimilar in its ...

In response to lawmakers' concerns, Pfizer and Eli Lilly said last week that they do not influence telehealth partners and ...

Ipsen has inked yet another licensing deal in an effort to bolster its cancer pipeline, this time for a preclinical T cell ...

Cartesian Therapeutics reported longer-term results from a mid-stage study of its mRNA CAR-T therapy for myasthenia gravis, ...

Relay Therapeutics licenses lirafugratinib to Elevar Therapeutics for $75m upfront and milestone payments, with potential ...

Roivant reported a Phase 2 failure on Tuesday for a program analysts expected would not succeed. The compound in question, ...

GSK has axed a Phase 2 study of a chronic hepatitis B therapeutic vaccine, adding to a string of treatment R&D hurdles for the liver infection.

Bristol Myers Squibb partners with AI Proteins for miniprotein development, with up to $400M in milestones. Terns Pharmaceuticals reports positive Phase 1 data for TERN-701. Six biotechs seek Hong ...

Revolution Medicines announced a $600M public offering following clinical data releases. Their lead drug RMC-6236 showed 38% ...

Apogee Therapeutics plans to challenge Sanofi and Regeneron's Dupixent with its lead drug APG777, an IL-13 targeting ...